The latest price target for Reviva Pharmaceuticals (NASDAQ:RVPH) was reported by D. Boral Capital on November 14, 2024. The analyst firm set a price target for $15.00 expecting RVPH to rise to within 12 months (a possible 1081.01% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Reviva Pharmaceuticals (NASDAQ:RVPH) was provided by D. Boral Capital, and Reviva Pharmaceuticals maintained their buy rating.

There is no last upgrade for Reviva Pharmaceuticals

The last downgrade for Reviva Pharmaceuticals Holdings Inc happened on August 16, 2024 when Maxim Group changed their price target from N/A to N/A for Reviva Pharmaceuticals Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reviva Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reviva Pharmaceuticals was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Reviva Pharmaceuticals (RVPH) rating was a maintained with a price target of $15.00 to $15.00. The current price Reviva Pharmaceuticals (RVPH) is trading at is $1.27, which is out of the analyst’s predicted range.